Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian Urological Association guideline: Erectile dysfunction. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CUA ED 2021
Source-attributed clinical priorities
- Assess onset, libido, erections, relationship context, medicines, substance use, endocrine and neurologic factors and cardiovascular risk.
- Address reversible contributors and offer a phosphodiesterase-5 inhibitor when suitable with correct-use counselling.
- Do not combine a phosphodiesterase-5 inhibitor with nitrates and refer complex, refractory, painful or anatomically abnormal presentations.
- Erectile dysfunction can be an early cardiovascular-risk marker and should prompt risk-factor assessment.
sources for this section:CUA ED 2021
Practical assessment and management workflow
1
Clarify onset, consistency, morning erections, libido, ejaculation, relationship context and distress.
2
Review diabetes, vascular, neurologic, endocrine, pelvic surgery, medicines and substance contributors.
3
Assess cardiovascular fitness for sexual activity and obtain targeted glucose, lipid or hormone tests.
4
Offer lifestyle and cause-directed care and teach correct use of an eligible first-line medicine.
sources for this section:CUA ED 2021
Safety, red flags and urgent escalation
- Never combine a phosphodiesterase-5 inhibitor with nitrates or recreational nitrites.
- New painful prolonged erection requires emergency treatment.
- Penile curvature, mass, severe endocrine findings or treatment failure may need specialist referral.
sources for this section:CUA ED 2021
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CUA ED 2021
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CUA ED 2021
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Urological AssociationCanadian Urological Association guideline: Erectile dysfunctionaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.